Clinical Study of Improved BEAM Conditioning Regimen for ASCT in Lymphoma

NCT05681403 | Not Yet Recruiting

• 1 other identifier: XJTU1AF2022LSK-238
• Study Type: interventional
• Target: 53
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single arm, open, single-center clinical study. The patients who are diagnosed with lymphoma and intend to undergo ASCT will be enrolled. The aim of this study is to investigate the efficacy and safety of the conditioning regimen using mitoxantrone hydrochloride liposome, BCNU, etoposide and cytarabine for ASCT.

Conditions

Lymphoma; Autologous Hematopoietic Stem Cell Transplantation

Outcome Measures

Primary Outcomes (1)

• recurrence rate

  The rate of lymphoma relapse

  From date of treating with conditioning regimen until lymphoma relapse, the end of follow-up or the date of death from any cause, whichever came first, assessed up to 36 months.

Secondary Outcomes (5)

• AEs

  From date of treating with conditioning regimen until the end of follow-up or the date of death from any cause, whichever came first, , assessed up to 36 months.

• Time of neutrophil implantation

  From date of the treatment with the conditioning regimen until the time of neutrophil implantation or date of death from any cause, whichever came first, assessed up to 36 months.

• Time of platelet implantation

  From date of the treatment with the conditioning regimen until the time of platelet implantation or date of death from any cause, whichever came first, assessed up to 36 months.

• OS

  From date of treating with conditioning regimen until the end of follow-up or the date of death from any cause, whichever came first, , assessed up to 36 months.

• PFS

  From date of treating with conditioning regimen until the end of follow-up or the date of death from any cause, whichever came first, , assessed up to 36 months.

Study Arms (1)

Improved BEAM regimen

EXPERIMENTAL

The enrolled subjects will received mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine as conditioning regimen for ASCT.

Drug: Improved BEAM regimen

Interventions

Improved BEAM regimen DRUG

Mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine will be used as conditioning regimen for ASCT in the lymphoma patients.

Also known as: Conditioning treatment with improved BEAM regimen

Improved BEAM regimen

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects volunteered to join the study, signed informed consent, had good compliance, and cooperated with follow-up.
• Aged 18-60 years, male or female.
• Subjects pathologically diagnosed non-Hodgkin's lymphoma, and intend to undergo autologous hematopoietic stem cell transplantation.
• ECOG score 0-1.
• Meet the following requirements: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 times the upper limit of normal value (ULN), total bilirubin (TBIL) ≤1.5×ULN (AST and ALT≤5×ULN are allowed if liver invasion occurs); serum creatinine ≤1.5×ULN; international normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5×ULN; ECG examination was normal or abnormal without clinical significance, cardiac ultrasound showed left ventricular ejection fraction (LVEF) greater than 60, or CK-MB is normal, pro-BNP less than 900 pg/mL.
• Female subjects have negative serum pregnancy test result. Subjects use highly effective birth control methods throughout the trial.

You may not qualify if:

• Previous recipients of mitoxantrone or mitoxantrone liposome; previous treatment with doxorubicin or other anthracyclines, with a cumulative dose of doxorubicin \> 360 mg/m2 (for other anthracyclines, 1 mg doxorubicin is equivalent to 2 mg epirubicin).
• Hypersensitivity to any study drug or its component.
• Uncontrolled systemic diseases (e.g., active infections, uncontrolled hypertension, diabetes, etc.) .
• Cardiac function and disease meet one of the following conditions: a) Long QTc syndrome or QTc interval \>480 ms; b) Complete left bundle branch block, degree II or III atrioventricular block; c) Severe uncontrolled arrhythmias that require medical treatment; d) New York College of Cardiology Grade ≥ III; e) Cardiac ejection fraction (LVEF) less than 60%; f) A history of myocardial infarction, unstable angina pectoris, severely unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically serious pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities within 6 months prior to recruitment.
• Active hepatitis B and C infection (positive HBV sAg and HBV-DNA more than 1x10\^3 copies/mL; HCV-RNA more than 1x10\^3 copies/mL) .
• Positive HIV antibody.
• Previous or current co-occurrence of other malignancies (except for effectively controlled non-melanoma basal cell carcinoma of the skin, breast/cervical carcinoma in situ, and other malignancies that have been effectively controlled without treatment in the past 5 years) .
• Primary or secondary central nervous system (CNS) lymphoma or a history of CNS lymphoma at the time of recruitment.
• Pregnant or lactating female subjects and those who do not want to take contraceptive measures.
• Drug abuse (non-medical use of narcotic drugs or psychotropic drugs) or drug dependence (sedative hypnotics, analgesics, anesthetics, excitants and psychotropic drugs, etc.).
• A history of mental disease or cognitive impairment.
• Other conditions that the investigator determined are not suitable for participation in the study.

Sponsors & Collaborators

• First Affiliated Hospital Xi'an Jiaotong University: lead

Study Sites (1)

First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, 710061, China

Location

MeSH Terms

Conditions

Lymphoma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Pengcheng He, MD

  First Affiliated Hospital Xi'an Jiaotong University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Pengcheng He, MD

CONTACT

0086-029-85324035; hepc@163.com

Xiaoyan Zheng, MD

CONTACT

0086-15829370502; xiaoy_2008@126.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 11, 2022
• First Posted: January 12, 2023
• Study Start: January 15, 2023
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: January 12, 2023

Record last verified: 2022-10

Locations

CN (1)